Scotoma analysis of 10-2 visual field testing with a white target in screening for hydroxychloroquine retinopathy

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 943-952

  Browning, David J ^a   Lee, Chong ^a  

^a Department of Ophthalmology Charlotte Eye Ear Nose and Throat Associates ^*  (United States)

Author keywords

10 2 visual field; Chloroquine; Hydroxychloroquine; Ideal body weight; Retinopathy; Toxicity

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; EYE FIXATION; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; PERIMETRY; QUANTITATIVE ANALYSIS; RETINOPATHY; RETROSPECTIVE STUDY; SCOTOMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

EID: 84930642648     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S82398     Document Type: Article

References (27)

1. Browning DJ. Hydroxychloroquine and Chloroquine Retinopathy. 1st ed. New York: Springer; 2014.
2. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol. 1987;104:139–144.
3. Mititelu M, Wong BJ, Brenner M, et al. Progression of hydroxychloroquine toxic effects after drug therapy cessation. New evidence from multimodal imaging. Arch Ophthalmol. 2013;131:1187–1197.
4. Xiaoyun MA, Dongyi HE, Linping HE. Assessing chloroquine toxicity in RA patients using retinal nerve fiber layer thickness, multifocal electroretinography and visual field test. Br J Ophthalmol. 2010;94: 1632–1636.
5. Lai TYY, Chan WM, Li H, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol. 2005;140:794–807.
6. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol. 2007;143:801–809.
7. Chen E, Brown DM, Benz MS, et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign). Clin Ophthalmol. 2010;4: 1151–1158.
8. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47:3531–3538.
9. Marmor MF, Kellner U, Lai TYY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415–422.
10. Browning DJ. Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155:418–428.
11. Lyons JS, Severns ML. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review.Doc Ophthalmol. 2009;118:29–36.
12. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133:649–656.
13. Browning DJ, Lee C, Rotberg D. The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. Clinical Ophthalmology. 2014;8:1401–1407.
14. Browning DJ. Reply to defining ideal body weight. Am J Ophthalmol. 2002;134:935–936.
15. Rao HL, Yadav RK, Begum VU, et al. Role of visual field reliability indices in ruling out glaucoma. JAMA Ophthalmol. 2015;133:40–44.
16. Heijl A, Patell VM. Essential Perimetry. 3rd ed. Dublin, CA: Carl Zeiss Meditec; 2002.
17. Murdoch IE, Morris SS, Cousens SN. People and eyes: statistical approaches in ophthalmology. Br J Ophthalmol. 1998;82:971–973.
18. Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12:294–304.
19. Marmor MF, Chien FY, Johnson MW. Value of red targets and pattern deviation pots in visual field screening for hydroxychloroquine retinopathy. JAMA Ophthalmol. 2013;131:476–480.
20. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–784.
21. Lai TYY, Ngai JWS, Chan WM, Lam DSC. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. Doc Ophthalmol. 2006;112:177–187.
22. Tanga L, Centofanti M, Oddone F, et al. Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine. Graefe’s Arch Clin Exp Ophthalmol. 2011;249: 715–721.
23. Saunders LJ, Russell RA, Crabb DP. Measurement precision in a series of visual fields acquired by the standard and fast versions of the Swedish interactive thresholding algorithm analysis of large-scale data from clinics.JAMA Ophthalmol. 2015;133:74–80.
24. Browning DJ, Lee C. The relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clinical Ophthalmology. 2014;8:1389–1399.
25. Easterbrook M, Tullo A. Value of Humprey perimetry in the detection of early chloroquine retinopathy. Lens Eye Toxic Res. 1989;6:255–268.
26. Anderson C, Blaha GR, Marx JL. Humphrey visual field findings in hydroxychloroquine toxicity. Eye. 2011;25:1535–1545.
27. Browning DJ, Lee C. Test-retest variability of multifocal electroretinography in normal volunteers and short-term variability in hydroxychloroquine users. Clinical Ophthalmology. 2014;8:1467–1473.